Key result
Proposed REASOH classification categorizes hypertension by etiology to guide personalized antihypertensive therapy.
Why the study?
Standardized treatment protocols do not address underlying pathophysiological states in some hypertensive patients, highlighting the need for pathogenetically guided drug selection in precision medicine.
The proposed REASOH classification offers a theoretical framework for personalized hypertension management based on underlying etiology.
With the epidemic of risk factors such as unhealthy lifestyle, obesity and mental stress, the prevalence of hypertension continues to rise across the world. Although standardized treatment protocols simplify the selection of antihypertensive drugs and ensure therapeutic efficacy, the pathophysiological state of some patients remains, which may also lead to the development of other cardiovascular diseases. Thus, there is an urgent need to consider the pathogenesis and selection of antihypertensive drug for different type of hypertensive patients in the era of precision medicine. We proposed the REASOH classification, based on the etiology of hypertension, including renin-dependent hypertension, elderly-arteriosclerosis-based hypertension, sympathetic-active hypertension, secondary hypertension, salt-sensitive hypertension and hyperhomocysteinemia hypertension. The aim of this paper is to propose a hypothesis and provide a brief reference for the personalized treatment of hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2023) conducted a review in Hypertension. REASOH classification was evaluated. The REASOH classification is proposed as a hypothesis to categorize hypertension based on etiology to guide personalized antihypertensive therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: